Ameluz aminolevulinic acid: Completed Phase III enrollment

Biofrontera completed enrollment of 52 patients in an observer-blind, European Phase III trial comparing topical Ameluz plus daylight PDT vs. topical Metvix methyl aminolevulinate plus daylight PDT. Patients receive each treatment to separate areas of the face or scalp containing 3-9 mild to moderate actinic keratosis lesions. ...